Skip to main content

Suppression of Ovulation

3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
2
10 µg/day E2 with NES 200® µg/dayPhase 21 trial
Nestorone®/Estradiol Contraceptive Vaginal RingPhase 21 trial
Active Trials
NCT01586000Completed197Est. May 2015
NCT02626208Completed65Est. Mar 2017
Theramex
TheramexUK - London
1 program
1
NOMACPhase 21 trial
Active Trials
NCT01361958Completed38Est. Sep 1998

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Human BioSciencesNestorone®/Estradiol Contraceptive Vaginal Ring
Human BioSciences10 µg/day E2 with NES 200® µg/day
TheramexNOMAC

Clinical Trials (3)

Total enrollment: 300 patients across 3 trials

NCT02626208Human BioSciencesNestorone®/Estradiol Contraceptive Vaginal Ring

Dose Finding Study of Contraceptive Vaginal Ring With Different Estradiol Levels in Combination With Nestorone

Start: Jan 2016Est. completion: Mar 201765 patients
Phase 2Completed
NCT01586000Human BioSciences10 µg/day E2 with NES 200® µg/day

A Dose-finding Study to Evaluate the Effect of a Contraceptive Vaginal Ring, Releasing Nestorone® and Estradiol, on Cycle Control, Ovulation Inhibition, and Pharmacokinetics in Normal Cycling Women

Start: Mar 2012Est. completion: May 2015197 patients
Phase 2Completed
NCT01361958TheramexNOMAC

Minimal Effective Dose of Nomegestrol Acetate Inhibiting the Ovulation in Women Receiving Estradiol

Start: Feb 1997Est. completion: Sep 199838 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.